MATTERHORN supports the global adoption of perioperative durvalumab plus FLOT as a new standard for patients with localized gastric and gastroesophageal junction adenocarcinoma,” said Yelena Y.

The supplemental Biologics License Application for the gastric/GEJ cancer indication is supported by data from the double-blind, placebo-controlled MATTERHORN trial.

The US Food and Drug Administration (FDA) has granted priority review to durvalumab for the treatment of patients with resectable, stage II-IVA gastric or gastroesophageal junction (GEJ) cancer.

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Early data from the DURIPANC study shows promising safety and survival benefits of rintatolimod and durvalumab for metastatic ...

In the EV-303/KEYNOTE-905 study, the combination of nectin-4-directed antibody-drug conjugate (ADC) Padcev (enfortumab ...

Immmunotherapy-based treatments demonstrate effectiveness and safety profiles consistent with clinical trials in real-world setting.

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

AstraZeneca (AZ) has announced that Imfinzi (durvalumab) in combination with Imjudo (tremelimumab) has been recommended by ...

AstraZeneca has received a positive recommendation from NICE for the use of Imfinzi (durvalumab) with Imjudo (tremelimumab) in adults with advanced or unresectable hepatocellular carcinoma (HCC). The ...

Mid-year report of combination therapy demonstrates promising signs of both no significant toxicity and superior PFS and OSOCALA, Fla., July 28, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE ...